Myriad Genetics Cut to Underweight as Piper Questions Path to Profit
Piper Sandler double-downgraded MYGN, saying the current model cannot grow or cut its way to profit.
/ 185 items
#XY Analyst Up/Down↓
Guggenheim Downgrades Tenax Therapeutics to Neutral After LEVEL Data at ESC 2026
Tenax’s TNX-103 missed the LEVEL primary endpoint. Guggenheim cites encouraging subgroup data in sicker patients but says more work and longer studies may be needed.
Novo Nordisk Gets Rare Sell Rating as Pipeline and Growth Concerns Mount
Analysts cite ziltivekimab’s trial miss, modest Medicare upside and patent risks.
Cardiol Therapeutics: B. Riley Sees 450% Upside as Phase 3 MAVERIC Trial Nears Completion
B. Riley initiates Cardiol Therapeutics at Buy with an $11 target, citing a de-risked Phase 3 MAVERIC trial and strong cash runway.
Agomab: Piper Sandler Sees 368% Upside on Ontunisertib for Fibrostenotic Crohn’s
Agomab trades at a deep discount to Sarepta and Abivax. Piper Sandler starts at Overweight with $60 PT.
Apnimed Stock Jumps After BofA and Cantor Kick Off Coverage with Big Upside Targets
BofA and Cantor Fitzgerald initiate coverage on Apnimed with Buy and Overweight ratings for Oxnimbi, its oral therapy for obstructive sleep apnea.